Table 2 Patient and procedural characteristics of interventions with complications
From: Transsplenic tract closure after transsplenic portalvenous access using gelfoam-based tract plugging
Intervention Number | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
Patient characteristics | ||||
Age (years) | 42 | 52 | 62 | 62 |
Gender | female | female | male | female |
Liver disease (cirrhotic / non-cirrhotic) | PVT (cirrhotic) | CTPV (non-cirrhotic) | Cryptogenic (cirrhotic) | CCC (non-cirrhotic) |
Pre-interventional characteristics | ||||
MELD | 18 | 10 | 25 | 5 |
INR | 1.51 | 1.31 | 1.15 | 0.86 |
aPTT (s) | 52 | 31 | 31 | 28 |
PLT (1*100/uL) | 31 | 40 | 86 | 146 |
Anti-aggregation/-coagulation pre-interventionally | Dalteparin, 10000IE, 1/d | Fondaparinux, 2.5mg, 1/d | Aspirin, 100mg, 1x/d | none |
Transfusion pre-interventionally | none | none | 2 pack of RBC | none |
Ascites pre-interventionally | present | present | present | none |
Spleen diameter (cm) | 25 | 18 | 15 | 10 |
Procedural characteristics | ||||
Indication | TIPS | VE” | VE | PVS |
Splenic access | successful | successful | successful | successful |
Interventional success | successful | successful | successful | successful |
Splenic access time (min) | 35 | 14 | 133 | 56 |
Total procedure time (min) | 322 | 110 | 205 | 113 |
Splenic access route | subcostal | intercostal | intercostal | intercostal |
Sheath Size (F) | 5-F | 4-F | 4-F | 7-F |
No. of gelfoam cubes | 2 | 2 | 2 | 2 |
Clinical significant complications | splenic hematoma | erysipelas, NP° | splenic hematoma, SBP^ | splenic hematoma |
CIRSE classification | 1 | 3 | 3 | 1 |